newsfilter
← Latest News
PR Newswire·

NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT

CLOSES EXCLUSIVE LICENSE OF ASSETS FROM DONG-A BOSTON, Nov. 8, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused